Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $39,460.60 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the sale, the insider now directly owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. The trade was a 3.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.76, for a total value of $8,254.40.

Travere Therapeutics Stock Down 0.4 %

Shares of Travere Therapeutics stock opened at $19.00 on Thursday. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $20.33. The business has a fifty day simple moving average of $18.17 and a 200 day simple moving average of $14.02. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.48 billion, a PE ratio of -4.18 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The company had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. During the same period in the prior year, the business posted ($1.17) EPS. Travere Therapeutics’s revenue was up 69.6% on a year-over-year basis. Research analysts predict that Travere Therapeutics, Inc. will post -3.94 EPS for the current year.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds have recently bought and sold shares of TVTX. Creative Planning increased its position in shares of Travere Therapeutics by 4.3% in the 3rd quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after buying an additional 995 shares in the last quarter. Forefront Analytics LLC increased its holdings in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after acquiring an additional 1,237 shares in the last quarter. Rice Hall James & Associates LLC raised its position in shares of Travere Therapeutics by 3.8% during the second quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company’s stock worth $626,000 after purchasing an additional 2,774 shares during the period. CWM LLC lifted its holdings in shares of Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares in the last quarter. Finally, Diversified Trust Co grew its position in shares of Travere Therapeutics by 27.5% in the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after purchasing an additional 3,169 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TVTX shares. Bank of America boosted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Guggenheim increased their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Piper Sandler boosted their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Citigroup decreased their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, September 27th. Finally, Scotiabank boosted their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.